Viela publishes Phase Ib data for CD40L antagonist in RA

Viela said the highest two doses of VIB4920 (formerly MEDI4920) significantly reduced disease activity in a Phase Ib trial to treat rheumatoid arthritis.

Data were published

Read the full 253 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE